Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So there is no knowing, only educated guesses and presumption or just hope for the powers that be to offer up news.
Please describe or define” macro-environment”?
Effect up down and why?
thanks
With the environment as is-
The NASDAQ down -31.--
No news, Fri. on its way
And it looking like many are panic buying with nothing really changed for supporting these levels I would think unless some good news popped up it will be back at mid 3.s by end of day Fr. Thoughts?
With no news, are the priceses we’v seen Wed & today all fluf?
Add to this, No News—
NASDAQ up +8.22
Any ideas WHY the price is climbing and how you can SEE WHO the Big Buyers are?
Thoughts on price holding or will we see drop back to low 3.20’s?
Is this a pump to dump?
@ 3.37 now
Thanks
ARIA’s waterline is coming up; it won’t sink
Stay long- don’t blink
Already back @ 3.20
It wasn’t ARIA sinking in the arctic storm that started yesterday. Its ship is sound; it took on some water and for its size got shoved and battered around by the huge waves. But if the ARIA long term crews stay with the ship, the storm will pass and the atmosphere will clear
US HOT STOCKS: Motorola, Owens Corning, Peet's, Whole Foods-3-
Last update: 8/4/2010 10:48:08 AM
Ariad Pharmaceuticals Inc. (ARIA, $3.35, +$0.13, +4.04%) posted second-quarter results that far exceeded analyst expectations as the company said they reflected the positive financial impact of its restructured agreement with Merck & Co. Inc. (MRK, $34.78, -$0.04, -0.11%) for the development, manufacture and commercialization of ridaforolimus in oncology.
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid=%7Ba511a015-6174-4a50-9626-558d70f9ba05%7D
That sounds upbeat
Anyone --- Throw a Number $$$$ --- Best Guess Survey ----for tomorrow?
BioTechHedge and glass_half_full, thank you both
Au-530
Can anyone explain this news break from “Fly on the wall”?
9:03 AM
http://www.theflyonthewall.com/permalinks/entry.php/ARIAid1273685/ARIA-Ariad-falls-
News Breaks July 26, 2010 09:02 EDT
Ariad falls 28.7%
Ariad is down 28.7%, or 92c, to $2.2900
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing
Subscribe for More Information
ARIAD to Webcast Conference Call on Second Quarter 2010 Financial ResultsLast update: 7/21/2010 7:35:00 AMCAMBRIDGE, Mass., Jul 21, 2010 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (ARIA) today announced that it will hold a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Wednesday, August 4, 2010. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company's financial results as of June 30, 2010, key corporate objectives and additional corporate activities. The Company will announce the highlights of these topics in a press release to be issued before the market opens on August 4, 2010 prior to the conference call. The live webcast can be accessed by visiting the investor relations section of the Company's website at . The call can be accessed by dialing 866-831-6224 (domestic) or 617-213-8853 (international) five minutes prior to the start time and providing the pass code 85617427. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need -- aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck and is in Phase 3 clinical development in patients with advanced sarcomas. ARIAD's second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. For additional information about the Company, please visit . SOURCE: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. Maria E. Cantor, 617-621-2208Copyright Business Wire 2010
Opinions please-
Closed @ 3.10 today, ask @3.14 –
Is this going to continue to inch up or would you think we will see a $ .10 .15 or.20 drop for a better buy opportunity by waiting?
Where can I go to look up all the abbreviations or short forms that are in these board postings?---- thank you in advance
Is the news you speak of fact or wishful thinking?
vidpok45 –
I’m sorry for my low IQ questions; I’ll try to listen and do as much DD on my own as I can.
I posted back on November 12, 2009. “I think this stock will bring good retunes as it continues to develop its formulas and I also like being associated with a company developing cures for cancer”.
I like being associated with a company developing a cure for cancer because-- #1- if it is as good a comp. as this looks to me (as unsophisticated as I am) then I want in!!!; #2- I think I’m going to make some $$$; and #3- I think there are enough smarter people then myself on this board for me to feel a good degree of confidence. Thank You-
Thank you Dough for your insight, and taking the time to respond to my post.
You did help
Thank you Dough for your insight, and taking the time to respond to my post.
You did help
Don Shimoda
Thank you for your bringing to light the next major catalysts include the start of the pivotal AP534 registration
It still gets hard to understand because much of your dialog is over our head.
If you could bring yourself to write a sort of undergrad types post – maybe ones or twice a day so get it in a more common tug- maybe just try it. If it not for you ,drop it!
Thanks Au-530
I was alone for a long time on this board but now it’s been very impressive reading some of the high IQ’s posting! I must admit, you (high IQ’s) are way above my pay grade but I am gleaning voluble insight. I got interested in ARIA about a year ago and still feel it going to be a good investment. I would appreciate any of you throwing out your wishful hopes for ARIA’s price and timeline for the future.
Thanks
Data on ARIAD's Oncology Pipeline to Be Presented at the 2010 ASCO Annual MeetingLast update: 5/21/2010 7:35:00 AMCAMBRIDGE, Mass., May 21, 2010 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (ARIA) today announced that new data on AP24534, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois being held June 4 to 8, 2010. The schedule and meeting location for the sessions, together with the abstract information, are listed below by program: AP24534 Title: Phase 1 trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and other hematologic malignancies Date & Time: Monday, June 7, 2010, 2:00 PM -- 6:00 PM (with presentation at 5:00 PM) Abstract: #53232 Presenter: Moshe Talpaz, M.D. (University of Michigan) Location: Exhibit Hall, 354a Ridaforolimus Title: A phase 1 study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotuzumab (DALO) in patients (pts) with advanced solid tumors Date & Time: Saturday, June 5, 2010, 1:30 PM - 2:00 PM Abstract: #48347 Presenter: Serena Di Cosimo, M.D. (Breast Cancer Center, Vall d'Hebron University Hospital) Location: Exhibit Hall, D2 Title: A multi-center, first-in-pediatrics phase 1 study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors Date & Time: Sunday, June 6, 2010, 5:00 PM -- 6:00 PM Abstract: #48828 Presenter: Lia Gore, M.D. (University of Colorado Denver and The Children's Hospital) Location: Room S 504 About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need -- aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIAD's second internally discovered product candidate, AP24534, is an investigational pan-BCR-ABL inhibitor completing Phase 1 clinical development in patients with hematological cancers, notably chronic myeloid leukemia. For additional information about the Company, please visit . SOURCE: ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc. Maria E. Cantor, 617-621-2208Copyright Business Wire 2010
Heard any informed guesses on $ uptick as time go’s on?
YES tullyman1, I’m sticking with ARIA, it will turn Gold in time!
There is life on this board
There's is life on this board
.07 Away from $3.00 W/1.831 mil volume – some day maybe $6. to $8. –any opinions?
Just hear to say I’m still holding – our day will come!
The last thing that went through the Fly mind when his head hit the windshield was his butt; get ready for a similar experience! You CAN’T WIN!!!!!!!!!! You WILL lose your money, and DELMAR will laugh all the way to the bank.
And with a great flushing sound BCZN heads for .0004 then .0003 – are we having fun yet?
Has everyone abandoned this chat room?
Anyone seen DELMAR Final January bank statement. I’ll bet it’s a lot more then his BizAuctions Final January eBay Sales, after dumping and dumping stock by the MIL!!!
Does anyone hear a flushing sound??????
YOU CAN’T !!!!!!!!!!! ---
-----Services are often PAID using FREE-trading SHARES. Since Gluckstein & Silverspoon Research may RECEIVE such compensation
and its employees or members of their families may hold stock in the profiled companies, there is an inherent CONFLLICT of Interest
IT'S LIKE THE UNDERWORLD CRIME!!!!
No you wont!
ALL of your CHART Smarts are worthless when the this over the counter stock is played like a game of chance that’s rigged; and DELMAR has 12 ACES and 4 jokers, up his sleeves; you CAN’T WIN. Focus on that; you CAN’T WIN!!!!!!!!!! You WILL lose your money and DELMAR will laugh all the way to the bank.
Remember the good old days @.0007, @.0008, @.0009, @.0010, @.0011, or even @0014 and all the happy news like saying “GREAT ENTRY FROM HERE!” or “I like to get in as or before the runs start”. DELMAR creams you with his DILUTION; there legal thieves. That’s DELMAR'S MAIN BUSINESS, ISSUING & SELLING BILLIONS OF SHARES OF WORTHLESS STOCK,
It’s time to cut your losses! This comp. is WORTHLESS. It’s just going DOWN and DOWN will it slowly picks up what money you still have. Then they just move on with there pockets stuffed with your money. “A fool and his money are soon parted.”
Other WORTHLESS chatter from Delmar PUMPERS
“Thanks for the great chart. I like to get in as or before the runs start.------------- This is it!”—---------WHAT RUN?
“I would be expecting updates from the company this week”--------------------EVERY NEWS update TOOK STOCK DOWN
“Should see that easily when it starts to go, just needs to break .0016” ------------------NEVER HAPPEN-
Cut your losses